Morgan Stanley Kal Vista Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 297,402 shares of KALV stock, worth $2.66 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

297,402

Previous 338,584 12.16%

Holding current value

$2.66 Million

Previous $3.99 Million 13.67%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$9.46 - $15.39 $389,581 - $633,790	-41,182 Reduced 12.16%	297,402 $3.44 Million
Q2 2024 Oct 17, 2024	SELL	$10.35 - $12.49 $888,547 - $1.07 Million	-85,850 Reduced 20.23%	338,584 $3.99 Million
Q2 2024 Aug 14, 2024	SELL	$10.35 - $12.49 $888,547 - $1.07 Million	-85,850 Reduced 20.23%	338,584 $3.99 Million
Q1 2024 Oct 17, 2024	BUY	$11.07 - $16.04 $950,359 - $1.38 Million	85,850 Added 25.36%	424,434 $5.03 Million
Q1 2024 Aug 16, 2024	SELL	$11.07 - $16.04 $309,960 - $449,120	-28,000 Reduced 6.19%	424,434 $5.03 Million
Q1 2024 May 15, 2024	SELL	$11.07 - $16.04 $309,960 - $449,120	-28,000 Reduced 6.19%	424,434 $5.03 Million
Q4 2023 Aug 16, 2024	BUY	$7.58 - $12.25 $862,983 - $1.39 Million	113,850 Added 33.63%	452,434 $5.54 Million
Q4 2023 Feb 13, 2024	BUY	$7.58 - $12.25 $1.84 Million - $2.97 Million	242,506 Added 115.52%	452,434 $5.54 Million
Q3 2023 Nov 15, 2023	BUY	$8.95 - $11.35 $65,379 - $82,911	7,305 Added 3.61%	209,928 $2.02 Million
Q2 2023 Aug 14, 2023	BUY	$7.73 - $10.57 $83,847 - $114,652	10,847 Added 5.66%	202,623 $1.82 Million
Q1 2023 May 15, 2023	SELL	$6.3 - $8.39 $4.04 Million - $5.39 Million	-641,977 Reduced 77.0%	191,776 $1.51 Million
Q4 2022 Feb 14, 2023	BUY	$4.2 - $14.24 $3.37 Million - $11.4 Million	802,871 Added 2599.8%	833,753 $5.64 Million
Q3 2022 Nov 14, 2022	SELL	$9.85 - $16.83 $280,104 - $478,594	-28,437 Reduced 47.94%	30,882 $448,000
Q2 2022 Oct 27, 2022	SELL	$8.16 - $15.1 $65,769 - $121,706	-8,060 Reduced 11.96%	59,319 $584,000
Q2 2022 Aug 15, 2022	SELL	$8.16 - $15.1 $65,769 - $121,706	-8,060 Reduced 11.96%	59,319 $584,000
Q1 2022 Oct 27, 2022	BUY	$11.2 - $16.97 $90,272 - $136,778	8,060 Added 13.59%	67,379 $993,000
Q1 2022 May 13, 2022	BUY	$11.2 - $16.97 $48,104 - $72,886	4,295 Added 6.81%	67,379 $993,000
Q4 2021 Feb 14, 2022	BUY	$12.36 - $18.28 $568,102 - $840,203	45,963 Added 268.46%	63,084 $835,000
Q3 2021 Nov 15, 2021	BUY	$17.11 - $24.49 $292,940 - $419,293	17,121 New	17,121 $300,000

Others Institutions Holding KALV

# of Institutions

125

Shares Held

47.8M

Call Options Held

551K

Put Options Held

110K

View Full List

About KalVista Pharmaceuticals, Inc.

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $220M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

More about KALV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account